



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/13, 47/14, 9/48 // (A61K 47/14, 47:10) (A61K 47/14, 47:26) (A61K 47/14, 47:10, 47:18)	A1	(11) International Publication Number: WO 97/26003 (43) International Publication Date: 24 July 1997 (24.07.97)
(21) International Application Number: PCT/GB97/00131 (22) International Filing Date: 17 January 1997 (17.01.97) (30) Priority Data: PV 169-96 18 January 1996 (18.01.96) CZ (71) Applicants (for all designated States except US): GALENA A S [CZ/CZ]; Ostravska 29, 747 70 Opava (CZ). NOR-TON HEALTHCARE LTD. [GB/GB]; Gemini House, Flex Meadow, Harlow, Essex (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): STUCHLIK, Milan [CZ/CZ]; Ratiborska 18, 746 01 Opava (CZ). ANDRYSEK, Tomas [CZ/CZ]; Rolnicka 36, 746 01 Opava (CZ). JEGOROV, Alexander [CZ/CZ]; Chlajna 8, 370 01 Ceske Budejovice (CZ). HUSEK, Ales [CZ/CZ]; Skrivanci 4, 746 01 Opava (CZ). MATHA, Vladimir [CZ/CZ]; Netolicka 5, 370 01 Ceske Budejovice (CZ). STUCHLIK, Josef [CZ/CZ]; Hrabyne 121, 747 63 Hrabyne (CZ). (74) Agent: BROWNE, Robin, Forsythe; Urquhart-Dykes & Lord, Tower House, Merion Way, Leeds LS2 8PA (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CYCLOSPORIN FORMULATION (57) Abstract <p>Therapeutical compositions comprising from 0.1 to 20 % by weight of a cyclosporin and a vehicle comprising from 1 to 60 % by weight of polyethers constituted by, preferably, substances like ethoxy diglycol or polyethylene glycols 300 to 600 and/or substances like preferably dimethyl isosorbide, dimethyl isodide and dimethyl isomannide, and from 1 to 60 % by weight of a mixture of glyceryl monoesters of C₈-C₂₂ fatty acids and hexaglyceryl to pentadecaglyceryl monoesters of C₈-C₂₂ fatty acids in a ratio of 1:2 to 1:6. The therapeutical compositions preferably additionally comprise further adjuvants like anti-oxidants, preserving agents and stabilisers, flavouring agents, thickening agents and diluents. The compositions for external use preferably additionally comprise lipoaminoacids.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

CYCLOSPORIN FORMULATION

This invention relates to a pharmaceutical formulation comprising a cyclosporin as active ingredient. The invention relates to formulations for internal use and also to topical formulations.

Cyclosporins are immunosuppressive cyclic undecapeptides which are used particularly in relation to organ transplants. Cyclosporins are also used for treatment of autoimmune diseases and inflammatory conditions such as arthritis and rheumatic diseases. Further applications include antiparasitic treatments and cancer therapy. Certain cyclosporins which are devoid of immunosuppressive activity have been found to exhibit an inhibitory effect towards replication of the HIV-1 virus and these compounds can be employed in therapy for treatment and prevention of AIDS or AIDS related diseases.

A wide variety of cyclosporins has been identified. Cyclosporins are highly hydrophobic and are consequently difficult to formulate in dosage forms providing adequate bioavailability. Solubility of cyclosporins in water typically does not exceed 25 mg/l. The high lipophilicity of cyclosporins is indicated by the value of the partition coefficient P in the system n -octanol/water. For cyclosporin, values of $\log P = 2.08$ to 2.99 have been reported.

Dispersion systems characterised by the presence of a hydrophilic phase, a hydrophobic phase and a tensoactive component have been used to afford acceptable bioavailability for cyclosporin formulations. Commercially available compositions for oral administration are available under the trade marks Sandimmun, Sandimmun-Neoral, Consupren, Implants and Imusporin. These formulations are disclosed in GB-A-2015339, GB-A-2222770, GB-A-2270842 and GB-A-2278780. A modification wherein the hydrophilic phase is omitted and replaced by partial esters of fatty acids with polyols such as propylene glycol, glycerol or sorbitol is disclosed in GB-A-2228198.

-2-

DE-A-4322826 discloses a carrier system for drugs which are poorly soluble in water, comprising a composition containing polyglyceryl esters of fatty acids as a co-tenside to non-ionic tensides having HLB higher than 10, in the presence of a triacyl glycerol as the lipophilic component. Use of dimethyl sorbide as a co-tenside is mentioned in GB-A-650721.

Compositions for external treatment of inflammatory skin diseases containing, as accelerators of percutaneous absorption, a combination of N-acyl sarcosine and salts thereof with fatty acid amides prepared as reaction products of aliphatic carboxylic acids with mono- and di-ethanolamides are disclosed in JP-A2-07025784.

It has been surprisingly found that it is possible to prepare cyclosporin formulations having advantages over prior compositions by modification of the lipidic components and omission of ethoxylated tensides from the formulation. While the solubility of cyclosporin in olive oil or corn oil does not exceed 50 mg/ml, we have discovered that solubility of cyclosporin in glyceryl monoesters is higher by approximately an order of magnitude.


According to the present invention a pharmaceutical composition containing cyclosporin for internal or external use is characterised in comprising from 0.1 to 20% by weight of a cyclosporin (I) and a vehicle comprising:

- (i) from 1 to 60% by weight of at least one polyether (II) of a general formula IIa



wherein n is an integer from 2 to 20, R is H or C₁-C₃ alkyl,

- (ii) and/or by a compound of general formula IIb



(IIb)

-3-

wherein R is C₁-C₃ alkyl;

(iii) and from 1 to 60% by weight of a mixture of one or more glyceryl monoesters of C₈-C₂₂ fatty acids (III) and one or more polyglyceryl esters selected from hexaglyceryl to pentadecaglyceryl monoesters of C₈-C₂₂ fatty acids (IV) in a ratio of components (III)/(IV) of 1:2 to 1:6.

We have found that mixtures of polar lipids formed by monoesters of fatty acids with glycerol and of pseudolipids formed by monoesters of fatty acids with polyglyceryl esters for example from hexaglycerol to pentadecaglycerol are particularly suitable for formulation of cyclosporin.

Cyclosporins which may be employed comprise one or more of: ciclosporin, [Nva]²-ciclosporin, [MeIle]⁴ ciclosporin, [3'-O-acylMeBmt]¹-ciclosporin.

The polyether IIa is preferably selected from: ethoxy diglycol or polyethylene glycols 300 to 600.

The compound of formula IIb is preferably selected from dimethyl isoidide, dimethyl isomannide and, more preferably, dimethyl isosorbide.

The compound of formula III is selected from: glyceryl monooctanoate, glyceryl monodecanoate, glyceryl monooleate and glyceryl monolinolate.

The compound of formula IV is selected from polyglyceryl monoesters preferably one or more of: hexaglyceryl monooleate, octaglyceryl monostearate, octaglyceryl monooleate, decaglyceryl monolaurate, decaglyceryl monomyristate, decaglyceryl monostearate and decaglyceryl monooleate.

The compositions may include one or more adjuvants (V) for example antioxidants, preserving agents, stabilizers, flavouring agents, thickening agents and diluents.

Compositions in accordance with this matter which are intended for external use may include lipoaminoacids (VI), obtained by an acylation of aminoacids or of protein hydrolyzates with C₈-C₂₂ fatty acids. The weight ratio of the compounds (I)/(VI) is preferably 1:1 to 1:3.

The lipoaminoacids (VI) are preferably selected from capryloyl glycine, dicapryloyl cystine, dipalmitoyl

-4-

hydroxyproline, lysine lauroyl methionate and dioctyldodecyl lauroyl glutamate.

The solvents from the group of polyethers serve to modify the physical characteristics of the formulation, especially in direct contact with the aqueous media of the gastro-intestinal tract or when diluting the concentrate before administration. The pharmacokinetic characteristics of compositions in accordance with the invention indicate reproducible absorption and good bioavailability.

Preferred compositions in accordance with this invention have as the vehicle lipids consisting of monoacyl glycerols wherein the acyl residue is C₈-C₂₂ and monoacyl glycerols with 6 to 15 glycerol units. Use of C₁₂-C₂₂ fatty acid monoglycerides is preferred although a proportion of shorter chain eg C₈-C₁₀ fatty acids may facilitate passage of the active composition through mucosal cells of the gastrointestinal tract into the blood stream. Advantageously, monoacyl glycerols used in the composition of this invention have a monoester content of at least 95%. Suitable products are for example commercial types of glyceryl monooleate (GMO, produced by Grinsted) having the following characteristics:

fatty acids composition	DIMODAN® GMO	DIMODAN® GMO 90
oleic	min 78%	min 92%
linoleic and linolenic	max 15%	- - -
linoleic	- - -	max 6%
saturated C ₁₆ , C ₁₈ , C ₂₀	max 10%	- - -
saturated C ₁₆ , C ₁₈	- - -	max 2%
free fatty acids cont	max 1.5%	max 0.5%

Similar products produced by Eastman under the trade names Myverol® 18-99 (glyceryl monooleate) or Myverol® 18-92 (glyceryl monolinoleate) with a minimal content of 90% monoesters can also be used.

Further products which are suitable as the polar lipidic component are monesters of polyglycerols of general formula



-5-

wherein $x = 3$ to 12 .

The polyglycerols are characterised by the following properties:

	mol weight	OH groups no	hydroxyl value
hexaglycerol	462	8	970
heptaglycerol	536	9	941
octaglycerol	610	10	920
nonaglycerol	684	11	903
decaglycerol	758	12	880
pentadecaglycerol	1228	17	846

Esters of polyglycerols with fatty acids are generally prepared either by partial esterification of the polyglycerols with corresponding saturated or unsaturated fatty acids or by transesterification of vegetable oils with polyglycerol. Each individual monoester of polyglycerol is characterised by its saponification number, the polymerisation degree in turn is best indicated by the hydroxyl value. Monoesters of polyglycerols especially suitable for the compositions of the invention are the following:

hexaglyceryl monooleate	NIKKOL® HEXAGLYN 1 - 0
octaglyceryl monostearate	SANTONE® 8-1-S
octaglyceryl monooleate	SANTONE® 8-1-0
decaglyceryl monolaurate	NIKKOL® DECAGLYN 1 - L
decaglyceryl monomyristate	NIKKOL® DECAGLYN 1 - M
decaglyceryl monostearate	NIKKOL® DECAGLYN 1 - S
decaglyceryl monooleate	NIKKOL® DECAGLYN 1 - 0

These polyglycerol monoesters are commercialised under the trade mark NIKKOL® by Nikko Chemicals Co Ltd and under the


-6-

trade mark SANTONE® by Durkee Foods.


The whole group of polyglycerol monesters, useful for the compositions of the invention, is characterised by the following purity tests:

acid number	max 6
heavy metals content	max 10 ppm
water content	max 2%
fatty acids Na salts content	max 2% (as Na stearate)
total ash	max 1%


Preferred compositions may include cyclic ethers obtained by alkoxylation of anhydro derivatives of alcoholic hexoses for example sorbitol, mannitol and iditol. Anhydriisation of sorbitol or of other alcoholic hexoses occurs under catalytic action of concentrated sulphuric acid giving



isosorbide
(exo-endo)



isoidide
(endo-endo)



isomannide
(exo-exo)

A subsequent reaction with, for example, methyl chloride gives 2,5-di-O-methyl derivatives, which are useful as solvents for cyclosporin formulations. An especially suitable product is 2,5-dimethyl isosorbide, produced under the trade mark ARLASOLVE® DMI by ICI.

It was surprisingly found in studies of the solubility of ciclosporin in 2,5-dimethyl isosorbide that, dependent on the water content, the solubility of ciclosporin has an anomalous behaviour and reaches a maximal value at a molar fraction of N

-7-

= 0.5. The solubility of ciclosporin slightly decreases with increasing concentration of dimethyl isosorbide and only 324 mg g⁻¹ dissolves in the anhydrous product at 20°C (see Table 1).

Table 1

Solubility of cyclosporin in a binary mixture 2,5-dimethyl isosorbide (DMI)/water

Concentration of DMI Molar fraction, N	Weight/%	Solubility of CyA [mg.g ⁻¹]
0.0	0.0	0.023
0.07	40	1.90
0.13	60	5.50
0.19	70	45.9
0.23	74	87.4
0.25	76	109.3
0.27	78	161.7
0.32	82	288.9
0.39	86	496.3
0.62	94	487.2
0.71	96	471.9
0.84	98	389.9
1.00	100	324.3

Ciclosporin forms, with 2,5-dimethyl isosorbide, a solvated form which crystallises in the monoclinic spatial group P2₁ with the following lattice parameters: a = 15.521 (2)Å, b = 20.833 (3)Å, c = 12.223 (3)Å, β = 100.21 °(1), Z = 2 (Huřak M, Kratochvil B, Jegorov A, Mařha V, Stuchlik M, Andrysek T: The structure of a new cyclosporin A solvated form, Zeitschrift fur Kristallographie, 211, 313-318, 1996).

-8-

The improvement of the solubility of cyclosporin in binary systems dimethyl isosorbide-water has a clear advantage when formulating soft gelatine capsules where migration of water from the gelatine layer into the mass of the capsule occurs.

A polyether from the group of general formula II especially preferred for the composition of the invention is ethoxy diglycol, known in the pharmaceutical trade under the trade name TRANSCUTOL® and commercialised by the French firm Gattefosse.

The solubility of cyclosporin in ethoxy diglycol alone is 578.5 mg.g⁻¹ at 20°C and is influenced in an insubstantial way by a small amount of water. Cyclosporin dissolves in a binary mixture of ethoxy diglycol with water at a concentration of ethoxy diglycol corresponding to a molar fraction of N = 0.5, 216 mg.g⁻¹ at 20°C.

Ethoxy diglycol which is preferred for use in accordance with this invention has the following physical and chemical characteristics:

density	0.88 - 0.989
refractive index	1.425 - 1.429
boiling point	295 - 202°C
acid value	max 0.1
peroxide value	max 12.5
water content	max 0.1
heavy metals content	max 10 ppm

Products from the group of polyethers of general formula IIa, also suitable for the compositions of the invention, are liquid to semi-solid polyethylene glycols having an average molecular weight of 200 to 600. These polyethers tend to form supersaturated solutions with cyclosporins, from which non-solvated orthorhombic forms may crystallise. Stabilisation of

these polyethylene glycol solutions is enabled by adding a small amount of propylene glycol, as is demonstrated in Table 2.

Table 2

Solubility of ciclosporin in binary mixture polyethylene glycol/propylene glycol

Concentration of PEG 400		Solubility of CyA [mg.g ⁻¹]
[N]	[%]	
0.0	0.0	214.5
0.021	10.0	186.1
0.045	20.0	194.5
0.059	25.0	182.1
0.11	40.0	186.2
0.16	50.0	182.4
0.22	60.0	189.0
0.31	70.0	185.6
0.36	75.0	182.7
0.43	80.0	183.6
0.63	90.0	172.9
1.0	100.0	131.2

Table 3

Physical and chemical characteristics of polyethylene glycols preferred for use in compositions of the invention

	hydroxyl value	density g/cm ³	viscosity mPa.s	solidification point/°C
PEG 200	534 - 591	1.124	60 - 70	-50
PEG 300	356 - 394	1.125	85 - 100	-15 - -10
PEG 400	267 - 295	1.126	110 - 125	4 - 8
PEG 600	178 - 197	1.126	16 - 19 *	17 - 22
PEG 1000	107 - 118	1.200	24 - 29 *	35 - 40

* 50% aqueous solution

For the compositions of the invention intended for external application to the skin and mucous membranes the vehicle as described above may be complemented with lipoaminoacids. These function as biovectors allowing passage through the skin and fixing the aminoacids in the upper layers of the epidermis. By their ampiphilic structure lipoaminoacids may be incorporated into the intercellular tissue and may play an important role in cohesion properties of corneocytes, and may thus contribute to the working of the hydroregulation and barrier function of the skin. By means of their bioaffinity to the skin lipoaminoacids may regulate the speed of penetration of the vehicle containing dissolved cyclosporin to the site of effect. The carboxyl functions of the lipoaminoacids are regulators of the desired pH reaction of the skin, thus contributing to the therapeutic effect of the immunomodulating drug.

Especially preferred lipoaminoacids are non-ionic derivatives of an N-acyl glutamic acid and higher fatty alcohols like, eg dioctyldodecyl lauroyl glutamate eg Amiter LGOD (trade mark of Ajinomoto) as a pseudolipidic component

-11-

compatible with monoesters of glycerol.

Other suitable lipoaminoacids for topical compositions of the invention are, eg, capryloyl glycine, dicapryloyl cystine, dipalmitoyl hydroxyproline, lysine lauroyl methionate, or N-acyl derivatives of aminoacids prepared from protein hydrolyzates like collagen or milk or wheat proteins. These products are commercialised, eg under the trade mark LIPACID® by the French firm Seppic.

This invention is further described by means of example but not in any limitative sense.

Example 1: Soft gelatine capsules

The following ingredients were used.

(I)	ciclosporin	10.00 g
(IIb)	dimethyl isosorbide	30.00 g
(III)	glyceryl monooleate	15.00 g
(IV)	decaglyceryl monooleate	44.40 g
(V)	tocopherol linoleate	0.60 g

The ingredients (III), (IV) and (IIb) were mixed at 50°C. To the resulting mixture, (I) and an anti-oxidating additive (V) were added and the mixture was stirred until dissolution under a blanket of an inert gas. The resulting product was filtered and filled into soft gelatine capsules.

Example 2: Oral solution

The following ingredients were used.

(I)	ciclosporin	10.00 g
(IIa)	polyethylene glycol 400	40.00 g
(III)	glyceryl monooleate	10.00 g
(IV)	decaglyceryl monooleate	30.00 g
(V)	propylene glycol	9.40 g
(V)	neohesperidine dihydrochalcone	0.20 g
(V)	tocopherol R,R,R- α	0.40 g

-12-

The ingredients (III), (IV) and (IIa) were mixed at 50°C. To the resulting mixture, (I) a mixture of adjuvants (V) was added. The resultant mixture was stirred until dissolution under a blanket of an inert gas. The resulting product was filtered and filled into glass vials.

Example 3: Ointment for external use.

An ointment with the following composition was prepared.

(I)	ciclosporin	3.00 g
(IIa)	ethoxy diglycol	12.00 g
(III)	glyceryl monolinolate	62.00 g
(IV)	decaglyceryl monolaurate	16.00 g
(VI)	di-octyldodecyl lauroyl glutamate	5.00 g
(VI)	caproyl glycine	2.00 g

Substances (III), (IV), (V), (VI) were melted at 50°C and mixed together. Substance (I) was dissolved individually in (II) and the resulting solution was homogenized with the melt and filled into suitable containers allowing external application.

The ointment was tested in comparison with a placebo. Albinotic guinea pigs were used for testing. The animals were sensitized at the bases of both ears with 50 μ l of 5% dinitrofluorobenzene (DNFB) and repeatedly with 2% DNFB dissolved in a 1:1 mixture acetone/olive oil. After 6 days the animals were shaved and epilated on both sides. On the following day, 20 μ l of 0.5% dinitrofluorobenzene dissolved in a 1:1 mixture acetone/olive oil was applied to both sides. Immediately after this application, 250 mg of the composition of Example 3 was applied to the right side of the guinea pig and 250 mg of the placebo composition of Example 3 to the left side of the guinea pig. Two control groups of the animals were used in testing the composition.

Negative control: the animals obtained 20 μ l of 0.5% dinitrofluorobenzene to both side.

Positive control: the animals were not treated with the

-13-

tested composition.

Erythemas at 24 and 32 hours after application of the compositions were evaluated.

Scale for evaluating erythema:

- 4 - dark red protruding stain
- 3 - red stain
- 2 - rose coloured stain
- 1 - small spots
- 0 - without any visible change

Evaluation of erythema:

	animals number	5% DNFB		2% DNFB	
		24 h	32 h	24 h	32 h
comp of ex 3	5	*0.2 0,05	*0.2 0.05	**0	**0
placebo, ex 3	5	1.3 1.03	1.1 0.64	1.7 0.82	1.3 1.3
negat control	5	0	0	0.2 0.05	0.2 0.06
posit control	5	2.49 0.52	2.1 0.88	2.2 0.63	1.5 0.71

The importance was evaluated by student's t-test against the placebo composition.

* - $p < 0.01$

** - $p < 0.001$

Evaluation of oedema was obtained by reading the values of skin thickness [mm] one day before application and the values of skin thickness at 8, 24, 32 and 48 h after application.

-14-

	number of animals (pieces)	8 h	24 h [mm]	32 h	48 h
comp of ex 3	5	0.11	0.42	0.33	0.24
placebo, ex 3	5	0.35	0.63	0.63	0.49
negat control	5	0.15	0.24	0.17	0.08
posit control	5	0.20	0.44	0.35	0.19

Example 4: Hard gelatine capsules

The following ingredients were used.

(I)	[Nva] ² -ciclosporin	15.00 g
(IIb)	dimethyl isosorbide 95%	35.00 g
(III)	glyceryl monocaprate	5.00 g
(III)	glyceryl monolinolate	12.00 g
(IV)	octaglyceryl monostearate	32.60 g
(V)	tocopherol R,R,R- α	0.40 g

Substances (IV) and (III) were melted at 50°C, mixed together and an anti-oxidant (V) added. To the resulting mixture a solution of (I) n (IIb) was added, homogenised and the product after filtration was filled into hard gelatine capsules at 50°C.

Example 5

The following ingredients were used.

(I)	ciclosporin	10.0 g
(II)	2,5-dimethyl isosorbide (95%)	30.0 g
(III)	glyceryl monooleate	20.0 g
(IV)	hexaglyceryl monooleate	40.0 g

The composition was filled into starch capsules CAPILL to give 50 mg cyclosporin in each capsule.

-15-

Pharmacokinetic evaluation of the composition and comparison with the commercial product was carried out after administering a single dose of 100 mg of cyclosporin in a two-phase cross-over experiment on 10 Beagle dogs. Male dogs of the age of 12 to 36 months and weighing 9 to 13 kg were fed a standard pelleted diet in the amount of 300 g daily, with water ad libitum.

The composition was administered after starving for 18 hr. Further food was given to the animals after an interval of 10 hr. Blood was taken from the forearm vein in the intervals 0, 0.5, 1, 2, 3, 5 and 8 hr. The blood samples were frozen at -20°C for storage prior to analysis of the cyclosporin content by liquid chromatography. Pharmacokinetic parameters were calculated by 1 compartment analysis using the programme KIN FIT and are as follows:

	AUC _{0-8h} [h.mg.l ⁻¹]	AUC _{0-∞} [h.mg.l ⁻¹]	T _{1/2El} [h]	Tmax [h]	Cmax [mg.l ⁻¹]
comp of ex 1	Ø 2.474 SD 1.022	4.274 2.037	4.822 1.994	1.953 1.505	0.465 0.157
commerc comp	Ø 2.900 SD 0.534	3.687 0.900	2.890 1.024	1.493 0.812	0.735 0.260

Explanation of abbreviations:

AUC area under curve
T_{1/2El} elimination half-time
Tmax time of attaining maximal concentration
Cmax maximal concentration
SD standard deviation
Ø average concentration

Example 6: Oral solution

The following ingredients were used.

-16-

(I)	ciclosporin	10.00 g
(IIa)	polyethylene glycol 400	19.70 g
(III)	glyceryl monooleate	16.10 g
(IV)	decaglyceryl monoolaurate	43.90 g
(V)	propylene glycol	10.00 g
(V)	hesperidine dihydrochalcone	0.30 g

Ingredients (III), (IV) and (IIa) were mixed together at 50°C. Ciclosporin (I) and both additives (V) were added and the mixture was stirred until dissolution of (II) under an inert gas blanket. The resultant mixture was filtered and filled into glass vials with gas-tight seals.

Pharmacokinetic evaluation of the composition of Example 6 in comparison with the commercial composition CONSUPREN solution was made in 10 Beagle dogs. Males aged two years and of a weight of 13 to 16.5 kg were fed with a standard feed with free access to water. Single administrations of both tested and compared compositions were made after 18 hr starvation. Further feed was given to the animals only after taking blood sample after 12th hour of administration. Blood was taken from the forearm vein in the intervals of 0, 1, 2, 3, 5, 8, 12 and 24 hr. The blood samples were stored at -20°C prior to analysis using the RIA kit by IMMUNOTECH for ciclosporin and its metabolites.

Individual blood levels (ng/ml) after single administration of 100 mg ciclosporin

COMPOSITION OF EXAMPLE 6								
time	1 hr	2 hr	3 hr	5 hr	8 hr	12 hr	24 hr	AUC ₀₋₂₄
levels of individual subjects	141	883	1423	997	683	498	189	10659
	1648	1631	1068	755	491	329	110	10382
	1244	1316	1018	685	515	391	143	9719
	1601	2000	1564	1021	677	498	152	13160
	1634	1250	884	664	454	328	96	10850
	774	1604	1388	830	514	356	116	11779
	50	1245	1208	765	534	384	108	15765
	1462	1309	1046	656	449	290	85	11588
	561	945	897	764	768	356	92	10609
	1444	1447	1030	567	369	267	73	11878
mean	1055.9	1363	1152.6	770.4	545.4	369.7	116.4	11638.7
SD	592.12	313.00	221.36	138.23	118.14	73.65	33.52	1653.13


REFERENCE COMPOSITION CONSUMPTION SOLUTION								
time	1 hr	2 hr	3 hr	5 hr	8 hr	12 hr	24 hr	AUC ₀₋₂₄
levels of individual subjects	502	972	860	667	454	338	91	9271
	125	613	1153	1377	1172	830	300	18452
	470	563	833	899	617	374	123	10420
	267	964	1144	1479	922	559	166	15340
	379	1028	898	601	380	244	73	7977
	221	816	1380	1372	640	769	242	16381
	461	1113	1440	863	638	413	137	12251
	216	743	706	503	278	250	76	6705
	726	1136	909	750	558	335	116	10430
	463	1315	1263	678	545	408	140	11379
mean	383	926.3	1058.6	918.9	620.4	452	146.4	11860.25
SD	169.12	227.96	238.66	340.06	246.62	193.68	69.38	3589.88

SD - standard deviation
AUC₀₋₂₄ area under curve

-19-


CLAIMS

1. A pharmaceutical composition containing cyclosporin for internal or external use, characterised in comprising from 0.1 to 20% by weight of a cyclosporin (I), and a vehicle comprising:
- (i) from 1 to 60% by weight of at least one polyether (II) of a general formula IIa



wherein n is an integer from 2 to 20, R is H or C₁-C₃ alkyl,

- (ii) and/or by a compound of general formula IIb



wherein R is C₁-C₃ alkyl;

- (iii) and from 1 to 60% by weight of a mixture of one or more glyceryl monesters of C₈-C₂₂ fatty acids (III) and one or more polyglyceryl esters selected from hexaglyceryl to pentadecaglyceryl monoesters of C₈-C₂₂ fatty acids (IV) in a ratio of components (III)/(IV) of 1:2 to 1:6.

2. A pharmaceutical composition as claimed in claim 1, characterised in that the cyclosporin (I) is selected from: ciclosporin, [NVa]²-ciclosporin, [MeIle]⁴-ciclosporin and [3'-O-acylMeBmt]¹-ciclosporin.

3. A pharmaceutical composition as claimed in claim 1 or 2 characterised in that the compound of formula IIa is selected from: ethoxy diglycol or polyethylene glycols 300 to 600.

-20-

4. A pharmaceutical composition as claimed in any preceding claim, wherein the compound of formula IIb is selected from: dimethyl isosorbide, dimethyl isoidide and dimethyl isomannide.

5. A pharmaceutical formulation as claimed in any preceding claim, characterised in that the compounds III are selected from: glyceryl monooctanoate, glyceryl monodecanoate, glyceryl monooleate and glyceryl monolinolate.

6. A pharmaceutical formulation as claimed in any preceding claim, wherein the compounds IV are selected from: hexaglyceryl monooleate, octaglyceryl monostearate, octaglyceryl monooleate, decaglyceryl monolaurate, decaglyceryl monomyristate, decaglyceryl monostearate and decaglyceryl monooleate.

7. The therapeutical compositions according to any preceding claim, further including one or more adjuvants (V) selected from: anti-oxidants, preserving agents, stabilisers, flavouring agents, thickening agents and diluents.

8. The therapeutical compositions for external use as claimed in any preceding claim, wherein the vehicle includes one or more lipoaminoacids (VI), obtained by an N-acylation of aminoacids or of protein hydrolyzates with C₈-C₂₂ fatty acids; the weight ratio of the compounds (I)/(VI) being 1:1 to 1:3.

9. A pharmaceutical composition as claimed in claim 8, characterised in that lipoaminoacids (VI) are selected from: capryloyl glycine, dicapryloyl cycstine, dipalmitoyl hydroxyproline, lysine lauroyl methionate and di-octyldodecyl lauroyl glutamate.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/00131

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K38/13 A61K47/14 A61K9/48 //(A61K47/14,47:10), (A61K47/14,47:26), (A61K47/14,47:10,47:18)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 650 721 A (HANMI PHARM. IND. CO., LTD.) 3 May 1995 see the whole document ---	1-9
A	EP 0 327 280 A (SANKYO COMPANY LIMITED) 9 August 1989 see the whole document ---	1-9
A	FR 2 636 534 A (SANDOZ) 23 March 1990 cited in the application see the whole document ---	1-9
A	GB 2 228 198 A (SANDOZ) 22 August 1990 cited in the application see the whole document ---	1-9
A	EP 0 451 461 A (BASF) 16 October 1991 see the whole document ---	1-9
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
22 April 1997	16.05.97	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer Moreau, J	

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 97/00131

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP 0 711 550 A (HANMI PHARM. IND. CO., LTD.) 15 May 1996 see the whole document ---	1-9
P,X	US 5 589 455 A (WOO J.S.) 31 December 1996 see the whole document -----	1-9

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 97/00131

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 650721 A	03-05-95	CN 1097597 A JP 8157358 A	25-01-95 18-06-96
EP 327280 A	09-08-89	JP 2049733 A AU 2885389 A CA 1326995 A US 4990337 A	20-02-90 03-08-89 15-02-94 05-02-91
FR 2636534 A	23-03-90	AU 627220 B AU 4140089 A BE 1003105 A BG 60525 B CA 1332150 A CH 679118 A CY 1711 A DE 3930928 A DK 171433 B FI 98046 B GB 2222770 A,B GR 1000456 B HK 86593 A HU 9500318 A IE 60764 B IL 91642 A JP 2121929 A JP 7025690 B LU 87586 A NL 8902315 A NO 180362 B PT 91731 B SE 8903042 A US 5342625 A	20-08-92 22-03-90 26-11-91 28-07-95 27-09-94 31-12-91 06-05-94 22-03-90 28-10-96 31-12-96 21-03-90 30-07-92 27-08-93 30-10-95 10-08-94 12-04-94 09-05-90 22-03-95 07-05-91 17-04-90 30-12-96 09-08-95 11-05-90 30-08-94
GB 2228198 A	22-08-90	BE 1005236 A CH 680650 A DE 4005190 A FR 2643262 A HK 149595 A IT 1240765 B JP 2255623 A	08-06-93 15-10-92 23-08-90 24-08-90 29-09-95 17-12-93 16-10-90

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 97/00131

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2228198 A		JP 6011703 B	16-02-94
EP 451461 A	16-10-91	DE 4005819 A	29-08-91
		DE 4023593 A	30-01-92
		DE 59101481 D	01-06-94
		ES 2052289 T	01-07-94
		US 5147644 A	15-09-92
EP 711550 A	15-05-96	CN 1128671 A	14-08-96
		JP 8310964 A	26-11-96
		US 5603951 A	18-02-97
US 5589455 A	31-12-96	NONE	